Recent Company News

• 02:16 PM ET Apr 10, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 12-Apr

• 09:21 AM ET Apr 02, 2026
  

  StreetAccount Summary - US Syndicate recap for 02-Apr

• 08:54 AM ET Apr 02, 2026
  

  StreetAccount Summary - US Initial Syndicate recap for 02-Apr

• 08:19 AM ET Apr 02, 2026
  

  StreetAccount Summary - US Pre-market trading

• 07:11 AM ET Apr 02, 2026
  

  Adagene announces offering of 18.7M ADSs priced at $3.75 per ADS ($4.61, 0.00)

• 07:07 AM ET Apr 02, 2026
  

  Adagene announces clinical collaboration with Incyte to evaluate muzastotug (ADG126) in combination with INCA33890 in patients with MSS CRC ($4.61, 0.00)

• 07:05 AM ET Apr 02, 2026
  

  Adagene announces updated data from Phase 1B/2 study of muzastotug + KEYTRUDA (pembrolizumab) in late-line patients with MSS CRC ($4.61, 0.00)

• 05:09 PM ET Apr 01, 2026
  

  Adagene reports FY EPS ($0.24) ex-items vs FactSet ($0.50) [2 est, ($0.55)-(0.45)] ($4.61, 0.00)

• 04:45 PM ET Mar 17, 2026
  

  Adagene to present two posters highlighting muzastotug at AACR Annual Meeting ($3.91, 0.00)

• 10:04 AM ET Mar 11, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (77 total)